Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD stock opened at $1.34 on Friday. The company has a market capitalization of $862,960.00, a price-to-earnings ratio of -0.08 and a beta of 0.70. Galmed Pharmaceuticals has a 52-week low of $1.28 and a 52-week high of $23.80. The company has a 50-day simple moving average of $2.22 and a two-hundred day simple moving average of $3.20.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.